Loading
French in vitro diagnostics company, best known for infection testing, whose THxID BRAF kit was a companion diagnostic for melanoma drugs.
bioMérieux describes itself as a world leader in in vitro diagnostics and dates its history to 1963 and the Mérieux family; its press releases are datelined Marcy-l'Étoile, France. Most of its products test for infections. In oncology its US arm held the approval for the THxID BRAF Kit (2013), a companion diagnostic for dabrafenib, trametinib and later encorafenib with binimetinib in melanoma, which the FDA PMA database records as withdrawn in June 2024.
bioMérieux's BRAF test for melanoma, approved with dabrafenib and trametinib in 2013; the FDA's device database records its approval as withdrawn in 2024.
Shares THxID BRAF Kit, Companion diagnostics, Melanoma.
Shares Companion diagnostics, Melanoma.
Shares THxID BRAF Kit, Melanoma.
Shares Companion diagnostics, Melanoma.
Shares THxID BRAF Kit, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/